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doi:10.1016/j.jtcvs.2006.06.030bjective: Application of the histoculture drug response assay for lung cancer was
nvestigated by using data acquired from lung cancer specimens.
ethods: From May 1994 through February 2005, histoculture drug response assay
ata were obtained from 359 lung cancer specimens held in our institute. We
xamined chemosensitivities of the tissues to cisplatin, doxorubicin, mitomycin C,
-fluorouracil, docetaxel, paclitaxel, etoposide, irinotecan, and gemcitabine. Cutoff
nhibition rates were determined with each drug for non–small cell lung cancer and
ere used to calculate predictabilities for chemotherapy responses.
esults: The evaluability of the histoculture drug response assay was high at 97.4%.
ood predictability, including true-positive and true-negative rates of 73.2% and
00%, respectively, with an accuracy of 83.0%, was observed.
onclusion: The histoculture drug response assay appears to be applicable to
on–small cell lung cancer for the prediction of responses to chemotherapy.
hemotherapy is not highly effective for the treatment of non–small cell lung
cancer (NSCLC). Sensitive drugs need to be identified and used for each
patient to improve responses to chemotherapy. In vitro drug response
ssays1-6 have been used for identification of such drugs. The histoculture 
esponse assay (HDRA)4-6 is a representative in vitro drug response assay me
sed for anticancer agents. Several clinical studies involving colorectal and gastric
ancers revealed that inhibition rates obtained with the HDRA can predict clinical
esponses to chemotherapy.4,5
Because the biologic characteristics of lung cancer are different from those of
olorectal and gastric cancers, it would be better to identify, before routine clinical
se, whether the HDRA is applicable and useful for lung cancer.
From May 1994, we instituted the HDRA for lung cancers, mainly using resected
urgical specimens obtained from patients with operable NSCLC.7-11 After data
cquisition, we investigated drug concentrations for the HDRA, cutoff inhibition
ates, and correlations among inhibition rates and clinical responses.
atients and Methods
atients
rom May 1994 through February 2005, 359 specimens obtained from patients with lung
ancer (257 male and 95 female patients ranging from 25-82 years old [average, 66  9
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TSears]) were used for the HDRA in our institute. The HDRA was
erformed on 352 of the specimens because 7 were too small.
here were 183 adenocarcinomas, 119 squamous cell carcinomas,
3 large cell carcinomas, 2 pleomorphic carcinomas, 2 adenosqua-
ous carcinomas, 18 small cell carcinomas, and 4 carcinomas of
nknown histology (NSCLC). Histologic data were not available
or 8 cases. Specimens were derived from primary lesions in 294
ases, metastatic lymph nodes in 42 cases, distant metastases in 15
ases, and pleural dissemination in 1 case. Chemotherapy had been
erformed before the HDRA in 7 cases. This study was approved
y our institutional review board for clinical practice, and written
nformed consent was obtained from the patients.
DRA
ethods for the HDRA were as reported by Furukawa and col-
eagues.5 Collagen sponge gels manufactured from pig skin w
urchased from Sumitomo Medical Inc. Cancerous portions of
pecimens were minced into pieces to approximately 10 mg, which
ere then placed on prepared collagen surfaces in 24-well micro-
lates. Plates were incubated for 7 days at 37°C in the presence of
rugs dissolved with RPMI 1640 medium containing 20% fetal
alf serum and left in a humidified atmosphere containing 95%
ir–5% CO2. Concentrations of drugs were 20 g/mL for cisplatin
CDDP), 300 g/mL for 5-fluorouracil (FU), 15 g/mL for adria-
ycin (ADM), 2 g/mL for mitomycin C (MMC), 500 g/mL for
toposide (VP-16), 0.2 g/mL for irinotecan (SN38), 100 g/mL
or docetaxel (DOC), 40 g/mL for paclitaxel (PAC), and 1000
g/mL for gemcitabine (GEM).
After histoculture, 100 L of Hank’s balanced salt solution
ontaining 0.1 mg/mL type I collagenase (Sigma) and 100 L of
-(4,5-Dimethyl-2-thiazotyl)-2,5-diphenyl-2H-tetrazoliumbromide
MTT) solution and dissolved in 5 mg/mL phosphate buffer solu-
ion were added to each culture well and incubated for another 16
ours. After extraction with dimethyl sulfoxide, absorbance of the
olution in each well was read at 540 nm. Absorbance per gram of
ultured tumor tissue was calculated from the mean absorbance of
issue from 4 culture wells, and the tumor-tissue weight was
etermined before culture.
The inhibition rate was calculated by using the following
ormula:
nhibition rate (%) (1Mean absorbance of treated tumor ⁄
Weight ⁄ Mean absorbance of control tumor ⁄ Weight) 100
The HDRA was regarded as evaluable when the mean absor-
ance of extracted formazan at 540 nm of the control tumor was 15
r more per gram. When the inhibition rate of the drug was a
egative value, it was regarded as zero, which meant absolutely no
hemosensitivity.
Data acquisitions of CDDP, FU, ADM, and MMC were started
Abbreviation and Acronyms
HDRA  histoculture drug response assay
NSCLC non–small cell lung cancer
SCLC  small cell lung cancern May 1994. That of VP-16 was started in August 1994, with a
04 The Journal of Thoracic and Cardiovascular Surgery ● FebrN38 started in December 1994, DOC in April 1996, GEM in July
000, and PAC in September 2000.
tatistical Analysis
ll values were reported as means  standard deviation (minimum-
aximum). The 2 test and analysis of variance were used to
valuate the significance of differences between groups.
esults
valuability of the HDRA
f the 352 cases, the assay failed in 3 cases because of
acterial contamination and in 2 cases because of insuffi-
ient cell viability. An average of 6.0  1.9 (min-max, 1-9)
rugs were tested in 347 cases. Among them, data were
udged as not reliable in 4 cases because control optical
ensity/weight was less than 15. Therefore there were 343
valuable specimens, and the evaluability of the HDRA was
7.4% (343/352).
etermination of Cutoff Inhibition Rates
ssay results from 315 NSCLC cases without prior chemo-
herapy were used to determine cutoff inhibition rates for
ach drug. Figure 1 shows the distribution of inhibition 
or each drug. Cutoff levels of drugs were determined
ccording to previously reported clinical response rates of
ach drug. Cutoff levels were determined a bit lower to
void false-negative cases. This resulted in a larger rate of
DRA-sensitive patients than reported clinical response
ates. Determined cutoff levels, average inhibition rates, and
ates of sensitive patients for each drug are summarized in
able 1.
By using these cutoff levels, an average of 2.2  2.0
min-max, 0-8) HDRA-positive drugs were obtained in 340
atients with available HDRA data. Distributions of posi-
ive drugs are shown in Figure 2. The modest popul
ncluded 88 (25.9%) cases with no positive drug.
linical Correlations
onsistency between HDRA results and clinical responses
as evaluated in 57 patients: 21 concurrent chemoradiation
CCRT) cases and 36 chemotherapy cases. The total number
f chemotherapy agents was 88, including 33 CCRTs and
5 chemotherapies. Numbers of uses of each drug were as
ollows: CDDP in 36 cases, MMC in 13 cases, DOC in 12
ases, VP-16 in 8 cases, PAC in 7 cases, ADM in 5 cases,
N38 in 3 cases, GEM in 2 cases, and FU in 2 cases.
Clinical responses were regarded as effective when a
omplete response or partial response was obtained and not
ffective when stable disease or progressive disease was
btained. In most cases treatment protocols contained more
han 1 drug. Therefore consistency with the HDRA was
udged according t o t h e rules summarized in Table 
hese rules might result in overestimations in diagnostic
ccuracies.
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G
TSClinical correlations are summarized in Table 3. Th
ere 11 true-positive cases, 29 true-negative cases, 15 false-
ositive cases, and no false-negative cases in 55 chemother-
py cases. There were 30 true-positive cases and 3 true-
egative cases in 33 CCRT cases. Neither false-positive
ases nor false-negative cases were observed. The yield was
n accuracy of 72.3% in chemotherapy and 100% in CCRT.
Figure 1. Distribution of inhibition rates for cisplatin (
(MMC), irinotecan (SN38), etoposide (VP-16), docetaxe
able 1. Inhibition rates of drugs
rug n IR < 0 IR
DDP 307 7 41.5 17.7 (
U 292 18 50.7  19.3 (
DM 235 10 49.8  20.6 (
MC 260 2 61.1 16.8 (
P-16 253 16 40.1  19.5 (
N38 232 27 40.6  21.4 (
OC 167 18 43.9  24.1 (
AC 68 2 69.3 22.8 (
EM 68 6 29.6 19.2 (
R, inhibition rates; CDDP, cisplatin; FU, 5-fluorouracil; ADM, adriamycin;
aclitaxel; GEM, gemcitabine.
The Journal of Thoracicood predictabilities were observed for both chemotherapy
nd CCRT.
The doctors could not avoid using negative agents for
hese 32 true-negative cases because there was no suitable
rotocol according to the HDRA results. Therefore a che-
otherapy protocol including negative agents was used
nder the informed consent of these patients.
), adriamycin (ADM), 5-fluorouracil (FU), mitomycin C
C), paclitaxel (PAC), and gemcitabine (GEM).
Cutoff > Cutoff Positive rate
3.0) 50 104 33.9
4.3) 60 97 33.2
2.9) 60 87 37
8.1) 70 121 46.5
2.0) 50 82 32.4
1.0) 50 74 31.9
9.1) 50 70 41.9
1.2) 70 43 63.2
8.9) 30 28 41.2
, mitomycin C; VP-16, etoposide; SN38, innotecan; DOC, docetaxel; PAC,CDDP
l (DO2.7-8
0.5-8
0.7-8
1.6-8
0.3-8
1.0-8
1.0-8
2.6-9
1.7-7
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G
TSAs for CDDP, for which the largest amount of data was
vailable, there were 17 true-positive cases, 5 false-positive
ases, and 14 true-negative cases. Yields of diagnostic prop-
rties were 77.2% (17/22) for positive predictive value,
00% (14/14) for negative predictive value, 100% (17/17)
or sensitivity, 73.7% (14/19) for specificity, and 79.5%
31/36) for accuracy.
iscussion
esponse rates for chemotherapy are usually lower for NSCLC
han for small cell lung cancer (SCLC). The new chemother-
py agents developed since 1994 (ie, taxanes, SN38, and
EM) have improved response rates for chemotherapy for
SCLC. However, a highly effective standard chemotherapy
able 2. Rules for judgment of clinical correlations
Clinical response
rug for judgment Combined drug Responder Nonresponder
ensitive Sensitive TP FP
Resistant TP FP
Unknown TP FP
esistant Sensitive NE TN
Resistant FN TN
Unknown NE TN
P, True positive; FP, false positive; NE, not evaluable; TN, true negative;
bN, false negative.
06 The Journal of Thoracic and Cardiovascular Surgery ● Febrrotocol for NSCLC has not been determined, and therefore
he HDRA should contribute to improvement of response rates
or chemotherapy in patients with NSCLC.
Several negative studies concerning chemosensitivity
ests for lung cancer were reported previously.12,13 The
ulture methods of these negative studies were different
rom our system. Their evaluabilities were quite inferior to
ur results. It seemed that this inferiority in culture tech-
ique might lead to their negative results.
The HDRA is one of the chemosensitivity tests for an-
icancer agents.4-6 It is characterized by its high evaluabi
ompared with other assay methods. A high evaluability
ate (97.4%) in lung cancer specimens was also demon-
trated in this study. This is thought to be due to advantages
f the histoculture method over other methods using single-
ell suspensions. Histoculture methods maintain cell-to-cell
ontacts, resulting in good cell viability. The high evalu-
bility of the HDRA is also thought to result from its good
redictability for clinical responses.
We used the HDRA for NSCLC in 19947-11 because of
ts reported high evaluability.4,5 The first step in the use
he HDRA for NSCLC was to adjust concentrations and
o determine cutoff inhibition rates for each drug to
SCLC. We identified these parameters by using surgical
pecimens from patients with resectable lung cancer.
For CDDP, FU, ADM, MMC, and PAC, concentrations to
Figure 2. Distributions of num-
bers of positive drugs.e used had already been decided from data obtained from
uary 2007
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G
TSther kinds of cancer, such as gastrointestinal cancers and
varian cancers. We checked whether the same concentrations
ould be used for NSCLC. Concentrations were initially de-
ided for NSCLC with DOC, VP-16, SN38, and GEM. As
hown in Figure 1, inhibition rates showed a broad distrib
ncluding nonresponding cases, and we then decided on cutoff
nhibition rates in NSCLC for all drugs.
In this article cutoff levels for NSCLC were decided by
sing data acquired from our institute. Cutoff inhibition
ates of several anticancer agents (ie, CDDP, DOC, PAC,
PT-11, and GEM) were decided according to response
ates of single-agent chemotherapy in NSCLC,14-22 and
hose for FU, ADM, MMC, and VP-16 were decided ac-
ording to those from combined chemotherapy. In this ret-
ospective analysis a good clinical correlation was observed
y using these cutoff inhibition rates. In particular, no
alse-negative cases were observed, as was reported in past
tudies on malignancies in the gastrointestinal tract. From
he results, it could be concluded that the HDRA was
pplicable to NSCLC.
In CCRT cases an accuracy of 100% was observed. This
esult was probably due to the small sample size of patients
ho were treated with HDRA-negative agents. Most CCRT
ases consisted of locally advanced diseases in this study. In
hese cases surgical resection of metastatic lymph nodes
as undergone only to obtain specimens for the HDRA, and
able 3. Clinical correlations
DRA results Response
ensitive Responder
CR
PR
Total
Nonresponder
SD
PD
Total
esistant Responder
CR
PR
Total
Nonresponder
SD
PD
Total
iagnostic accuracies
Positive predictive value
Negative predictive value
Sensitivity
Specificity
Accuracy
DRA, Histoculture drug response assay; CCRT, concurrent chemoradia
rogressive disease.hen HDRA-positive agents were intentionally used for b
The Journal of Thoracic,
CRT.9,10 This treatment strategy gave rise to the sma
ample size of patients using HDRA-negative agents. More-
ver, cutoff inhibition rates in HDRA in this article were
etermined not for CCRT but for chemotherapy. Response
ates of CCRT are usually superior to those of chemother-
py in NSCLC, and thus we believe that false-negative
ases can occur in future studies using larger sample sizes.
The inhibition rate of SCLC was significantly lower than
hat of NSCLC with CDDP (P  .02), FU (P  .04), ADM
P  .0003), and MMC (P  .004). This result indicated
hat NSCLC was more highly sensitive to chemotherapy
ompared with SCLC. This result was not consistent with
linical observations. Therefore we speculate that the cutoff
nhibition rates for NSCLC determined in this article could
ot be applied for SCLC, and we could not determine cutoff
nhibition rates for SCLC in this article because of the
nsufficient number of samples.
For high evaluability, the HDRA requires large amounts
f biopsy specimens. An average of 100 mg of specimen
ith good cell viability is needed to evaluate the sensitivity
f 1 drug, whereas more than 1 drug requires another 40 mg
f specimen. This large requirement limits applications of
he HDRA. To obtain sufficient specimens for the HDRA,
ome surgical procedures must be used even for inoperable
ases because bronchoscopic biopsy specimens or needle
Chemotherapy cases CCRT cases Total
1 1 2
10 29 39
11 30 41
11 0 11
4 0 4
15 0 15
0 0 0
0 0 0
0 0 0
15 3 18
14 0 14
29 3 32
42.3% 100% 73.2%
100% 100% 100%
100% 100% 100%
65.9% 100% 68.1%
72.7% 100% 83.0%
CR, complete response; PR, partial response; SD, stable disease; PD,tion;iopsy specimens are not applicable for the HDRA.
and Cardiovascular Surgery ● Volume 133, Number 2 307
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G
TSSome recent articles revealed that gene expression mi-
roarray analysis data might predict the chemosensitivity in
ung cancer.23,24 This can be accomplished on much sma
mounts than needed for the HDRA and therefore might
ecome a good option for chemosensitivity testing in lung
ancer.
It has already been reported that the HDRA improves the
rognosis of patients with gastrointestinal cancer.4,5 Our
esults demonstrated that the HDRA was applicable to
SCLC and that it might contribute to the improvement of
esponses to chemotherapy. However, it remains unclear
hether HDRA-orientated chemotherapy will improve the
rognosis of patients with NSCLC. Further data acquisition
n respect to the clinical results of chemotherapy is needed
o better evaluate this.
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